With pricing starting a only $400, there’s a little something for everyone, though the systems are skewed toward home entertainment and business solutions:
To justify its volley of all-in-one machines, HP cited figures from IDC and NPD that indicate a rise of consumer interest in compact computing solutions. According to IDC, 15.7% of commercial PC users around the globe intend to purchase an all-in-one in the next 12 months, up from 9.9%. Meanwhile, NPD’s research shows that 34% of consumer desktop purchases in July were all-in-ones.
The discrete solution is undoubtedly a step up from Sandy Bridge’s integrated engine, but it can only deliver modest frames when playing modern games on high or ultra quality (~30 frames per second or lower in most titles tested by Notebookcheck).
Quelling those concerns, the company has introduced an updated version of the machine with a speedier GPU. The GT780DX sheds Nvidia’s GT 555M in favor of the new GTX 570M, which carries over triple the CUDA cores, has a higher graphics clock, a broader memory bus and more VRAM. According to Nvidia’s published 3DMark Vantage scores, the GTX 570M effectively doubles the GT 555M’s performance.
Additionally, it seems MSI has streamlined the machine’s storage options. Instead of an array of mechanical drives, systems will come with a 500GB or 7500GB 7200RPM HDD alongside a 120GB Intel SSD. Other core specifications remain unchanged, including the Core i7-2630QM processor, 17.3-inch 1600×900 or 1920×1080 display, a DVD or Blu-ray drive, a 720p webcam and the usual cornucopia of connectivity.
The recycled specs also include SteelSeries’ gaming-oriented keyboard, which includes LED lighting that can be configured in various color schemes. Beyond the eye candy, the keyboard offers improved tactile feedback, an ergonomic “golden triangle” gaming cluster, support for 10 simultaneous key presses (presumably limited to gaming-specific keys), and a durable design in case you’re prone to rage-induced tantrums.
More than 1.5 million people will be diagnosed with breast cancer this year worldwide. Scientists don’t know why most women get breast cancer, yet breast cancer is the most frequent tumor found in women the world over. A woman who dies of breast cancer is robbed of an average of nearly 20 years of her life. Breast cancer knows no social boundaries. It’s a disease that can affect anyone. Some prominent women who’s lives that have been touched by breast cancer include Jill Eikenberry actress age 52; Peggy Fleming age 49 figure skater; Kate Jackson age 50 (Charlies Angels); Olivia Newton-John age 50 actress singer; Nancy Reagan age 77 former first lady; Melissa Etheridge age 43 singer; and the beautiful Suzanne Summers actress. These high rates of breast cancer are not acceptable to the women of the world and must be met with scientific research that provides results.
Breast Cancer The Cure
Despite over a decade of research, and more than $1.7 billion spent, hundereds of women worldwide are dying from breast cancer every day. Yet doctors don’t know how breast cancer starts or how to cure it. Doctors are still approaching treatment for breast cancer in the same old fashioned ways: surgery, radiation, and chemotherapy. Barbarick treatments…And scientists keep doing the same old redundant research that’s simply not working. It doesn’t have to be that way. Gen Cells Cures is a scientific biotechnology company that is focused on a cure for breast cancer. The company is dedicated to curing breast cancer before it’s too late for you. We’re not interested in a cure in five, ten, or twenty years from now. We want your cure for breast cancer within a year or two. We don’t want you to have to under go surgery, radiation, chemotherapy or take toxic drugs.
Why Gen Cells Cures? You can search the medical journals; you can search the internet until your blue in the face. You will find the same old news which is no new news about breast cancer research and treatments. Breast cancer research is locked up in a black whole. Gen Cells Cures is approaching the cure for breast cancer from different angles and using tomorrow’s scientific technologies today. Our expertise is in stem cell research and genomics. Malfunctioning stem cells have already been linked to the development of breast cancer. We’re not talking about using generic stem cells from an egg and sperm cell. There is no genetic match for you with the politically controversial generic stem cells that are always in the news. The isolation of cancer stem cells, coupled with our understanding of genetic mutations causing cancer, and our knowledge of genomics will result in ways to eliminate cancer cells while sparing normal breast tissues.
People will tell you to accept what you can’t change…Your genetics, your genes, the genes your mother and father handed you when you were born that came with their particular genetic make-up. Most inherited cases of breast cancer have been associated with two genes: BRCA1 and BRCA2. The past five years has been a period of unparalleled discovery in the field of genetics, genomics, and stem cell research, but these discoveries are not being applied to breast cancer treatments. A job that Gen Cells Cures definitely wants to get our hands dirty in. Recently researchers have found that by blocking a gene called beta1-integrin the growth of tumor cells can be stopped. When this gene was removed the tumor cells quit growing. You don’t have to accept the genes that you were given at birth. Gen Cells Cures will be able to manipulate your genes to cure your breast cancer.
